BCT score predicts chemotherapy benefit in Asian patients with hormone receptor-positive, HER2-negative, lymph node-negative breast cancer.
The Breast Cancer Test (BCT) score has been validated for its ability to predict the risk of distant metastasis in hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative early breast cancer. This study aimed to examine the value of the BCT score for predicting the benefi...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2018-01-01
|
| Series: | PLoS ONE |
| Online Access: | http://europepmc.org/articles/PMC6248959?pdf=render |
| _version_ | 1818691818352541696 |
|---|---|
| author | Mi Jeong Kwon Sae Byul Lee Jinil Han Jeong Eon Lee Jong Won Lee Gyungyub Gong Peter D Beitsch Seok Jin Nam Sei Hyun Ahn Byung-Ho Nam Young Kee Shin |
| author_facet | Mi Jeong Kwon Sae Byul Lee Jinil Han Jeong Eon Lee Jong Won Lee Gyungyub Gong Peter D Beitsch Seok Jin Nam Sei Hyun Ahn Byung-Ho Nam Young Kee Shin |
| author_sort | Mi Jeong Kwon |
| collection | DOAJ |
| description | The Breast Cancer Test (BCT) score has been validated for its ability to predict the risk of distant metastasis in hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative early breast cancer. This study aimed to examine the value of the BCT score for predicting the benefit of adjuvant chemotherapy for Korean women with hormone receptor-positive, HER2-negative, lymph node-negative breast cancer. The study included 346 patients treated with either hormone therapy alone (n = 203) or hormone therapy plus chemotherapy (n = 143), and compared patient survival between the two treatment groups. The effect of BCT score on patient survival by treatment group was assessed using Cox proportional hazards models. Based on the results, the BCT score was prognostic for distant metastasis-free survival and breast cancer-specific survival in the hormone therapy alone group. There was no significant difference between the treatment groups in terms of 10-year distant metastasis-free survival in the overall patient population. However, when patients were classified as low risk (n = 266) and high risk (n = 80) according to the BCT score, addition of adjuvant chemotherapy to hormone therapy for patients classified as BCT high-risk group led to a significant improvement in 10-year distant metastasis-free survival, from 65.4% to 91.9% (hazard ratio, 0.18; 95% confidence interval, 0.05-0.64; P = 0.003); in contrast, there was no benefit for the BCT low-risk group. The stratification of patients according to the BCT score also identified clinically high-risk patients who may not benefit from chemotherapy. Results were similar for breast cancer-specific survival. In conclusion, the BCT score was not only of prognostic value but was also a predictor of chemotherapy benefit for Korean patients with hormone receptor-positive, HER2-negative, lymph node-negative breast cancer. |
| first_indexed | 2024-12-17T12:47:56Z |
| format | Article |
| id | doaj.art-598981f0399b476082fb17b5dbbf71ec |
| institution | Directory Open Access Journal |
| issn | 1932-6203 |
| language | English |
| last_indexed | 2024-12-17T12:47:56Z |
| publishDate | 2018-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj.art-598981f0399b476082fb17b5dbbf71ec2022-12-21T21:47:41ZengPublic Library of Science (PLoS)PLoS ONE1932-62032018-01-011311e020715510.1371/journal.pone.0207155BCT score predicts chemotherapy benefit in Asian patients with hormone receptor-positive, HER2-negative, lymph node-negative breast cancer.Mi Jeong KwonSae Byul LeeJinil HanJeong Eon LeeJong Won LeeGyungyub GongPeter D BeitschSeok Jin NamSei Hyun AhnByung-Ho NamYoung Kee ShinThe Breast Cancer Test (BCT) score has been validated for its ability to predict the risk of distant metastasis in hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative early breast cancer. This study aimed to examine the value of the BCT score for predicting the benefit of adjuvant chemotherapy for Korean women with hormone receptor-positive, HER2-negative, lymph node-negative breast cancer. The study included 346 patients treated with either hormone therapy alone (n = 203) or hormone therapy plus chemotherapy (n = 143), and compared patient survival between the two treatment groups. The effect of BCT score on patient survival by treatment group was assessed using Cox proportional hazards models. Based on the results, the BCT score was prognostic for distant metastasis-free survival and breast cancer-specific survival in the hormone therapy alone group. There was no significant difference between the treatment groups in terms of 10-year distant metastasis-free survival in the overall patient population. However, when patients were classified as low risk (n = 266) and high risk (n = 80) according to the BCT score, addition of adjuvant chemotherapy to hormone therapy for patients classified as BCT high-risk group led to a significant improvement in 10-year distant metastasis-free survival, from 65.4% to 91.9% (hazard ratio, 0.18; 95% confidence interval, 0.05-0.64; P = 0.003); in contrast, there was no benefit for the BCT low-risk group. The stratification of patients according to the BCT score also identified clinically high-risk patients who may not benefit from chemotherapy. Results were similar for breast cancer-specific survival. In conclusion, the BCT score was not only of prognostic value but was also a predictor of chemotherapy benefit for Korean patients with hormone receptor-positive, HER2-negative, lymph node-negative breast cancer.http://europepmc.org/articles/PMC6248959?pdf=render |
| spellingShingle | Mi Jeong Kwon Sae Byul Lee Jinil Han Jeong Eon Lee Jong Won Lee Gyungyub Gong Peter D Beitsch Seok Jin Nam Sei Hyun Ahn Byung-Ho Nam Young Kee Shin BCT score predicts chemotherapy benefit in Asian patients with hormone receptor-positive, HER2-negative, lymph node-negative breast cancer. PLoS ONE |
| title | BCT score predicts chemotherapy benefit in Asian patients with hormone receptor-positive, HER2-negative, lymph node-negative breast cancer. |
| title_full | BCT score predicts chemotherapy benefit in Asian patients with hormone receptor-positive, HER2-negative, lymph node-negative breast cancer. |
| title_fullStr | BCT score predicts chemotherapy benefit in Asian patients with hormone receptor-positive, HER2-negative, lymph node-negative breast cancer. |
| title_full_unstemmed | BCT score predicts chemotherapy benefit in Asian patients with hormone receptor-positive, HER2-negative, lymph node-negative breast cancer. |
| title_short | BCT score predicts chemotherapy benefit in Asian patients with hormone receptor-positive, HER2-negative, lymph node-negative breast cancer. |
| title_sort | bct score predicts chemotherapy benefit in asian patients with hormone receptor positive her2 negative lymph node negative breast cancer |
| url | http://europepmc.org/articles/PMC6248959?pdf=render |
| work_keys_str_mv | AT mijeongkwon bctscorepredictschemotherapybenefitinasianpatientswithhormonereceptorpositiveher2negativelymphnodenegativebreastcancer AT saebyullee bctscorepredictschemotherapybenefitinasianpatientswithhormonereceptorpositiveher2negativelymphnodenegativebreastcancer AT jinilhan bctscorepredictschemotherapybenefitinasianpatientswithhormonereceptorpositiveher2negativelymphnodenegativebreastcancer AT jeongeonlee bctscorepredictschemotherapybenefitinasianpatientswithhormonereceptorpositiveher2negativelymphnodenegativebreastcancer AT jongwonlee bctscorepredictschemotherapybenefitinasianpatientswithhormonereceptorpositiveher2negativelymphnodenegativebreastcancer AT gyungyubgong bctscorepredictschemotherapybenefitinasianpatientswithhormonereceptorpositiveher2negativelymphnodenegativebreastcancer AT peterdbeitsch bctscorepredictschemotherapybenefitinasianpatientswithhormonereceptorpositiveher2negativelymphnodenegativebreastcancer AT seokjinnam bctscorepredictschemotherapybenefitinasianpatientswithhormonereceptorpositiveher2negativelymphnodenegativebreastcancer AT seihyunahn bctscorepredictschemotherapybenefitinasianpatientswithhormonereceptorpositiveher2negativelymphnodenegativebreastcancer AT byunghonam bctscorepredictschemotherapybenefitinasianpatientswithhormonereceptorpositiveher2negativelymphnodenegativebreastcancer AT youngkeeshin bctscorepredictschemotherapybenefitinasianpatientswithhormonereceptorpositiveher2negativelymphnodenegativebreastcancer |